Assay of tumor markers (CEA, CA 15-3, CA 125 and CA 19-9) in malignant effusions and cerebrospinal fluid by aid of Kryptor™: Correlation with cytologic results and blood concentrations;Dosage des marqueurs tumoraux ACE, CA 15.3, CA 125 et CA 19.9 dans les liquides d'épanchement et le LCR par immunoanalyse en phase homogène. Corrélation avec les résultats cytologiques et les concentrations sériques

Immuno-Analyse et Biologie Specialisee

Volumn 17, Issue 1, 2002, Pages 18-25

  Guepratte, S ^a   Pallud, C ^a   Pichon, M F ^a  

^a CENTRE RENÉ HUGUENIN   (France)

Author keywords

Ascites; Cerebrospinal fluid; Pleural effusion; Tumor markers

Indexed keywords

CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

ARTICLE; ASCITES; ASSAY; BLOOD LEVEL; CANCER CELL; CANCER PATIENT; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CIRCULATION; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOLOGY; EFFUSION; FREEZING; HEMOCONCENTRATION; HUMAN; HUMAN CELL; IMMUNORADIOMETRIC ASSAY; PERFORMANCE; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN CONTENT; SAMPLE; SENSITIVITY ANALYSIS;

EID: 1342329886     PISSN: 09232532     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0923-2532(02)01162-6     Document Type: Article

References (20)

1. Whiteside T.L., Dekker A. Diagnostic significance of carcinoembryonic antigen levels in serous effusions. Correlations with cytology. Acta Cytologica. 23:1979;443-448.
2. Ammon A., Eiffert H., Reil S., Beyer J.H., Droese M., Hiddemann W. Tumor-associated antigens in effusions of malignant and benign origin. Clin. Investig. 71:1993;437-444.
3. Ferrer J., Villarino A., Encabo G., Felip E., Bermejo B., Vilz S., et al. Diagnostic utility of Cyfra 21-1, carcinoembryonic antigen, CA 125, neuron specific enolase, and squamous cell antigen level determinations in the serum and pleural fluid of patients with pleural effusions. Cancer. 86:1999;1488-1495.
4. Stanford C.F., Munro Neville A., Laurence D.J.R. Concurrent assays of plasma and pleural-effusion levels of carcinoembryonic antigen in the diagnosis of pulmonary disease. Lancet. 2:1978;53-53.
5. Klockars M., lindgren J., Petterson T., Hellstrom P.E., Norhagen A. Carcinoembryonic antigen in pleural effusions. Lancet. 2:1978;1057-1058.
6. Tamura S., Nishigaki T., Moriwaki Y., Fujioka H., Nakano T., Fujii J., et al. Tumor markers in pleural effusion diagnosis. Cancer. 61:1988;298-302.
7. Toumbis M., Chondros K., Ferderigos A.S., Danagou M., Dema A., Dalamaga A., et al. Clinical evaluation of four tumor markers in malignant and benign pleural effusions. Anticancer Res. 12:1992;1267-1270.
8. Menard O., Dousset B., Jacob C., Martinet Y. Improvement of the diagnosis of the cause of pleural effusion in patients with lung cancer by simultaneous quantification of carcinoembryonic antigen (CEA) and neuron-specific enolase (NSE) pleural levels. Eur. J. Cancer. 29A:1993;1806-1809.
9. Villena V., Lopez-Encuentra A., Echave-Sustaeta J., Martin-Escribano P., Ortuno-de-Solo B., Estenoz-Alfaro J. Diagnostic value of CA 72-4, carcinoembryonic antigen, CA 15-3, and CA 19.9 assay in pleural fluid. Cancer. 78:1996;736-740.
10. Romero S., Fernandez C., Arriero J.M., Espaa A., Candela A., Martin C., et al. CEA, Ca 15-3 and Cyfra 21-1 in serum and pleural fluid of patients with pleural effusions. Eur Respir J. 9:1996;17-23.
11. Salama G., Miédougé M., Rouzaud P., Mauduyt M.A., Pujazon M.C., Vincent C., et al. Evaluation of pleural Cyfra 21-1 and carcinoembryonic antigen in the diagnosis of malignant pleural effusions. Br J Cancer. 77:1998;472-476.
12. Miédougé M., Rouzaud P., Salama G., Pujazon M.C., Vincent C., Mauduyt M.A., et al. Evaluation of seven tumor markers in pleural fluid for the diagnosis of malignant effusions. Br J Cancer. 81:1999;1059-1065.
13. Booth S.N., Lakin G., Dykes P.W., Burnett D., Bradwell A.R. Cancer-associated proteins in effusion fluids. J Clin Pathol. 30:1977;537-540.
14. Bergmann J.F., Bidart J.M., George M., Beaugrand M., Levy V.G., Bohuon C. Elevation of CA 125 in patients with benign and malignant ascites. Cancer. 59:1987;213-217.
15. Mezger J., Permanetter W., Gerbes A.L., Wilmanns W., Lamerz R. Tumour associated antigens in diagnosis of serous effusions. J Clin Pathol. 41:1988;633-643.
16. Ferroni P., Szpak C., Greiner J.W., Simpson J.F., Guadagni F., Johnston W.W., et al. CA 72-4 radioimmunoassay in the diagnosis of malignant effusions. Comparison of various tumor markers. Int J Cancer. 46:1990;445-451.
17. Martinez-Vea A., Gatell J.M., Segura F., Heiman C., Elena M., Ballesta A.M., et al. Diagnostic value of tumoral markers in serous effusions. Cancer. 50:1982;1783-1788.
18. Mathis G. Rare earth cryptates and homogeneous fluoroimmunoassays with human sera. Clin Chem. 39:1993;1953-1959.
19. Gherardi C., Roumier A.S., Dubucquoi S., Dessaint J.P. Les cryptates appliqués au dosage des marqueurs tumoraux (ACE, AFP, CA 15.3, CA 19.9) : évaluation de lautomate Kryptor (Cis-Bio). Ann Biol Clin (Paris). 56:1998;92-95.
20. Kierkegaard O., Mogensen O., Mogensen B., Ahrons S. can manipulation of a pelvic tumour influence the serum level of cancer antigen 125 and cancer-associated serum antigen ? Br J Cancer. 77:1998;2012-2013.